Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo

Leukemia

Volumn 17, Issue 1, 2003, Pages 26-38

  Mortreux, F ^a,c   Gabet, A S ^a   Wattel, E ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c FUND FOR SCIENTIFIC RESEARCH   (Belgium)

Author keywords

Adult T cell leukemia; Genetic variability; HTLV 1; Leukemogenesis; Mutation

Indexed keywords

DNA; VIRUS DNA;

CANCER CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL TRANSPORT; CHROMOSOME ABERRATION; CLONAL VARIATION; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC STABILITY; HOST CELL; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IN VIVO STUDY; LATENT PERIOD; LEUKEMOGENESIS; MOLECULAR MECHANICS; PATHOGENESIS; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROVIRUS; REVERSE TRANSCRIPTION; REVIEW; SOMATIC MUTATION; SYMPTOM; T CELL LEUKEMIA; T CELL LYMPHOMA; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD;

EID: 0037265658     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402777     Document Type: Review

References (102)

1. Loeb LA. Cancer cells exhibit a mutator phenotype. Adv Cancer Res 1998; 72: 25-56.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-7421.
3. Yoshida M, Mioshi I, Hinuma Y. Isolation and characterisation of a retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-2040.
4. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de Thé G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407-410.
5. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-1 infection. Lancet 1990; 336: 1345-1347.
6. Mattos K, Queiroz C, Pecanha-Martins AC, Publio L, Vinhas V, Melo A. Lymphocyte alveolitis in HAM/TSP patients. Preliminary report. Arq Neuropsiquiatr 1993; 51: 134-136.
7. Mochizuki M, Tajima K, Watanabe T, Yamaguchi K. Human T lymphotropic virus type 1 uveitis. Br J Ophthalmol 1994; 78: 149-154.
8. Sato K, Maruyama I, Maruyama Y, Kitajima I, Nakajima Y, Higaki M, Yamamoto K, Miyasaka N, Osame M, Nishioka K. Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum 1991; 34: 714-721.
9. Sherman MP, Amin RM, Rodgers-Johnson PE, Morgan OS, Char G, Mora CA, Iannone R, Collins GH, Papsidero L, Gibbs CJ Jr, Poiesz BJ. Identification of human T cell leukemia/lymphoma virus type I antibodies, DNA, and protein in patients with polymyositis. Arthritis Rheum 1995; 38: 690-698.
10. Takatsuki K, Yamaguchi K, Kawano F, Hattori T, Nishimura H, Tsuda H, Sanada I, Nakada K, Itai Y. Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res 1985; 45: 4644S-4645S.
11. Shimoyama M, Kagami Y, Shimotohno K, Miwa M, Minato K, Tobinai K, Suemasu K, Sugimura T. Adult T-cell leukemia/lymphoma not associated with human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1986; 83: 4524-4528.
12. Blattner WA. Human T-lymphotrophic viruses and diseases of long latency. Ann Intern Med 1989; 111: 4-6.
13. Cavrois M, Gessain A, Wain-Hobson S, Wattel E. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene 1996; 12: 2419-2423.
14. Cavrois M, Wain-Hobson S, Gessain A, Plumelle Y, Wattel E. Adult T-cell leukemia/lymphoma on a background of clonally expanding human T-cell leukemia virus type-1-positive cells. Blood 1996; 88: 4646-4650.
15. Cavrois M, Leclercq I, Gout O, Gessain A, Wain-Hobson S, Wattel E. Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with Tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene 1998; 17: 77-82.
16. Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, Mueller N, Takatsuki K, Matsuoka M. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res 1997; 57: 4862-4867.
17. Furukawa Y, Fujisawa J, Osame M, Toita M, Sonoda S, Kubota R, Ijichi S, Yoshida M. Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP). Blood 1992; 80: 1012-1016.
18. Montreux F, Leclercq I, Gabet A, Leroy A, Westhof E, Gessain A, Wain-Hobson S, Wattel E. Somatic mutation in human T-cell leukemia virus type 1 provirus and flanking cellular sequences during clonal expansion in vivo. J Natl Cancer Inst 2001; 93: 367-377.
19. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69: 2863-2868.
20. Wattel E, Cavrois M, Gessain A, Wain-Hobson S. Clonal expansion of infected cells - a way of life for HTLV-1. J Acquir Immune Defic Syndr Hum Retrovir 1996; 13 (Suppl. 1): 92-99.
21. Wattel E. Proliferation of HTLV-1 infected cells in vivo: pathogenic implications in leukemogenesis and neuropathogenesis. ABI Professional Publications: Arlington, 1999.
22. Jeang KT, Widen SG, Semmes OT, Wilson SH. HTLV-1 trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990; 247: 1082-1084.
23. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1. Cell 1998; 93: 81-91.
24. Kao SY, Marriott SJ. Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein. J Virol 1999; 73: 4299-4304.
25. Miyake H, Suzuki T, Hirai H, Yoshida M. Trans-activator Tax of human T-cell leukemia virus type 1 enhances mutation frequency of the cellular genome. Virology 1999; 253: 155-161.
26. Philpott SM, Buehring GC. Defective DNA repair in cells with human T-cell leukemia/bovine leukemia viruses: role of tax gene. J Natl Cancer Inst 1999; 91: 933-942.
27. PiseMasison CA, Choi KS, Radonovich M, Dittmer J, Kim SJ, Brady JN. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol 1998; 72: 1165-1170.
28. Ressler S, Morris CF, Marriott SJ. Human T-cell leukemia virus type 1 Tax transactivates the human proliferating cell nuclear antigen promoter. J Virol 1997; 71: 1181-1190.
29. Majone F, Jeang KT. Clastogenic effect of the human T-cell leukemia virus type I Tax oncoprotein correlates with unstabilized DNA breaks. J Biol Chem 2000; 275: 32906-32910.
30. Uittenbogaard MN, Giebler HA, Reisman D, Nyborg JK. Transcriptional repression of p53 by human T-cell leukemia virus type I Tax protein. J Biol Chem 1995; 270: 28503-28506.
31. Domingo E, Holland JJ. Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. In: Setlow JK (ed.). Genetic Engineering, Principles and Methods. Plenum Press: New York, 1992, pp 13-31.
32. Holland JJ, de le Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992; 176: 1-20.
33. Eigen M. Viral quasispecies. Sci Am 1993; 269: 42-49.
34. Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc Natl Acad Sci USA 1999; 96: 13910-13913.
35. Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci USA 1983; 80: 3618-3622.
36. Gessain A, Gallo RC, Franchini G. Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 1992; 66: 2288-2295.
37. Pedroza Martins L, Chenciner N, Wain-Hobson S. Complex intrapatient sequence variation in the V1 and V2 hypervariable regions of the HIV-1 gp 120 envelope sequence. Virology 1992; 191: 837-845.
38. Wattel E, Mariotti M, Agis F, Gordien E, Le Coeur FF, Prin L, Rouger P, Chen IS, Wain-Hobson S, Lefrere JJ. Quantification of HTLV-1 proviral copy number in peripheral blood of symptomless carriers from the French West Indies. J Acquir Immune Defic Syndr 1992; 5: 943-946.
39. Albrecht B, Collins ND, Newbound GC, Ratner L, Lairmore MD. Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. J Virol Meth 1998; 75: 123-140.
40. + lymphocytes in the spinal cord from patients with HTLV-1-associated myelopathy. J Neuroimmunol 1994; 53: 23-29.
41. Kira J, Koyanagi Y, Yamada T, Itoyama Y, Goto I, Yamamoto N, Sasaki H, Sakaki Y. Increased HTLV-1 proviral DNA in HTLV-1-associated myelopathy: a quantitative polymerase chain reaction study (published erratum appears in Ann Neurol 1991; 29, 363). Ann Neurol 1991; 29: 194-201.
42. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4: 586-593.
43. Gabet AS, Mortreux F, Talarmin A, Plumelle Y, Leclercq I, Leroy A, Gessain A, Clity E, Joubert M, Wattel E. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 2000; 19: 4954-4960.
44. Mansky LM. In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy. J Virol 2000; 74: 9525-9531.
45. Mansky LM. Sorting out mutations in human T-cell leukemia virus type 1 proviruses during in vivo clonal expansion. J Natl Cancer Inst 2001; 93: 336-337.
46. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-5094.
47. Coffin JM. Genetic variation in avian retroviruses. Dev Biol Stand 1990; 72: 123-132.
48. Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 1992; 188: 628-636.
49. + cytotoxic T lymphocytes specific for HTLV-1 pX in patients with HTLV-1 associated neurological disease. Nature 1990; 348: 245-248.
50. Kazanji M, Ureta-Vidal A, Ozden S, Tangy F, de Thoisy B, Fiette L, Talarmin A, Gessain A, de Thé G. Lymphoid organs as a major reservoir for human T-cell leukemia virus type 1 in experimentally infected squirrel monkeys (Saimiri sciureus): provirus expression, persistence, and humoral and cellular immune responses. J Virol 2000; 74: 4860-4867.
51. Mortreux F, Kazanji M, Gabet AS, de Thoisy B, Wattel E. Two-step nature of human T-cell leukemia virus type 1 replication in experimentally infected squirrel monkeys (Saimiri sciureus). J Virol 2001; 75: 1083-1089.
52. Kazanji M, Moreau JP, Mahieux R, Bonnemains B, Bomford R, Gessain A, de Thé G. HTLV-1 infection in squirrel monkeys (Saimiri sciureus) using autologous, homologous, or heterologous HTLV-1-transformed cell lines. Virology 1997; 231: 258-266.
53. Kazanji M, Tartaglia J, Franchini G, de Thoisy B, Talarmin A, Contamin H, Gessain A, de Thé G. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). J Virol 2001; 75: 5939-5948.
54. Hollsberg P, Hafler DA. Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 1993; 328: 1173-1182.
55. Cavrois M, Gessain A, Gout O, Wain-Hobson S, Wattel E. Common human T cell leukemia virus type 1 (HTLV-1) integration sites in cerebrospinal fluid and blood lymphocytes of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis indicate that HTLV-1 crosses the blood-brain-barrier via clonal HTLV-1-infected cells. J Infect Dis 2000; 182: 1044-1050.
56. Leclercq I, Mortreux F, Morschhauser F, Duthilleul P, Desgranges C, Gessain A, Cavrois M, Vernant JP, Hermine O, Wattel E. Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL). Br J Haematol 1999; 105: 743-751.
57. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19: 475-496.
58. Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR. Abundant tax protein expression in CD4+ T cells infected with human T- cell lymphotropic virus type I (HTLV-1) is prevented by cytotoxic T lymphocytes. Blood 2000; 95: 1386-1392.
59. Fujii M, Niki T, Mori T, Matsuda T, Matsui M, Nomura N, Seiki M. HTLV-1 Tax induces expression of various immediate early serum responsive genes. Oncogene 1991; 6: 1023-1029.
60. Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. Embo J 1986; 5: 2883-2888.
61. Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. Embo J 1996; 15: 1607-1614.
62. Santiago F, Clark E, Chong S, Molina C, Mozafari F, Mahieux R, Fujii M, Azimi N, Kashanchi F. Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells. J Virol 1999; 73: 9917-9927.
63. Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, Jeang KT. Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb. Mol Cell Biol 1998; 18: 3620-3632.
64. Haller K, Wu Y, Derow E, Schmitt I, Jeang KT, Grassmann R. Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol Cell Biol 2002; 22: 3327-3338.
65. Van PL, Yim KW, Jin DY, Dapolito G, Kurimasa A, Jeang KT. Genetic evidence of a role for ATM in functional interaction between human T-cell leukemia virus type 1 Tax and p53. J Virol 2001; 75: 396-407.
66. Koralnik IL, Gessain A, Klotman ME, Lo Monico A, Berneman ZN, Franchini G. Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I. Proc Natl Acad Sci USA 1992; 89: 8813-8817.
67. Derse D, Mikovits J, Ruscetti F. X-I and X-II open reading frames of HTLV-1 are not required for virus replication or for immortalization of primary T-cells in vitro. Virology 1997; 237: 123-128.
68. Cockerell GL, Rovnak J, Green PL, Chen IS. A deletion in the proximal untranslated pX region of human T-cell leukemia virus type II decreases viral replication but not infectivity in vivo. Blood 1996; 87: 1030-1035.
69. Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore MD. Selective ablation of human T-cell lymphotropic virus type 1 p121 reduces viral infectivity in vivo. Blood 1998; 91: 4701-4707.
70. Pique C, Ureta-Vidal A, Gessain A, Chancerel B, Gout O, Tamouza R, Agis F, Dokhelar MC. Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides. J Exp Med 2000; 191: 567-572.
71. Lairmore MD, Albrecht B, D'Souza C, Nisbet JW, Ding W, Bartoe JT, Green PL, Zhang W. In vitro and in vivo functional analysis of human T cell lymphotropic virus type 1 pX open reading frames I and II. AIDS Res Hum Retrovir 2000; 16: 1757-1764.
72. Albrecht B, Collins ND, Burniston MT, Nisbet JW, Ratner L, Green PL, Lairmore MD. Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol 2000; 74: 9828-9835.
73. Albrecht B, D'Souza CD, Ding W, Tridandapani S, Coggeshall KM, Lairmore MD. Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein p12(I). J Virol 2002; 76: 3493-3501.
74. Askjaer P, Kjems J. Mapping of multiple RNA binding sites of human T-cell lymphotropic virus type I rex protein within 5′- and 3′-Rex response elements. J Biol Chem 1998; 273: 11463-11471.
75. Ahmed YF, Hanly SM, Malim MH, Cullen BR, Greene WC. Structure-function analyses of the HTLV-1 Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev 1990; 4: 1014-1022.
76. Ballaun C, Farrington GK, Dobrovnik M, Rusche J, Hauber J, Bôhnlein E. Functional analysis of human T-cell leukemia virus type I rex-response element: direct RNA binding of Rex protein correlates with in vivo activity. J Virol 1991; 65: 4408-4413.
77. Hanly SM, Rimsky LT, Malim MH, Kim JH, Hauber J, Duc Dodon M, Le SY, Maizel JV, Cullen BR, Greene WC. Comparative analysis of the HTLV-1 Rex and HIV-1 Rev trans- regulatory proteins and their RNA response elements. Genes Dev 1989; 3: 1534-1544.
78. Toyoshima H, Itoh M, Inoue J, Seiki M, Takaku F, Yoshida M. Secondary structure of the human T-cell leukemia virus type 1 rex-responsive element is essential for rex regulation of RNA processing and transport of unspliced RNAs. J Virol 1990; 64: 2825-2832.
79. Inoue J, Yoshida M, Seiki M. Transcriptional (p40x) and posttranscriptional (p27x-III) regulators are required for the expression and replication of human T-cell leukemia virus type I genes. Proc Natl Acad Sci USA 1987; 84: 3653-3657.
80. Baskerville S, Zapp M, Ellington AD. High-resolution mapping of the human T-cell leukemia virus type 1 Rex-binding element by in vitro selection. J Virol 1995; 69: 7559-7569.
81. Bogerd HP, Tiley LS, Cullen BR. Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element. J Virol 1992; 66: 7572-7575.
82. Giallongo A, Oliva D, Cali L, Barba G, Barbieri G, Feo S. Structure of the human gene for alpha-enolase. Eur J Biochem 1990; 190: 567-573.
83. Cavrois M, Wain-Hobson S, Wattel E. Stochastic events in the amplification of HTLV-1 integration sites by linker-mediated PCR. Res Virol 1995; 146: 179-1784.
84. Furukawa Y, Kubota R, Tara M, Izumo S, Osame M. Existence of escape mutant in HTLV-1 tax during the development of adult T-cell leukemia. Blood 2001; 97: 987-993.
85. D'Incan M, Combemale P, Verrier B, Garin D, Audoly G, Brunot J, Desgranges C, Flechaire A. Transient adult T-cell leukemia/lymphoma picture during varicella infection in an HTLV-1 carrier. Leukemia 1994; 8: 682-687.
86. Hanabuchi S, Ohashi T, Koya Y, Kato H, Takemura F, Hirokawa K, Yoshiki T, Yagita H, Okumura K, Kannagi M. Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade. J Virol 2000; 74: 428-435.
87. Jenks PJ, Barrett WY, Raftery MJ, Kelsey SM, van-der-Walt JD, Kon SP, Breuer J. Development of human T-cell lymphotropic virus type I-associated adult T-cell leukemia/lymphoma during immunosuppressive treatment following renal transplantation. Clin Infect Dis 1995; 21: 992-993.
88. Tsurumi H, Tani K, Tsuruta T, Shirato R, Matsudaira T, Tojo A, Wada C, Uchida H, Ozawa K, Asano S. Adult T-cell leukemia developing during immunosuppressive treatment in a renal transplant recipient. Am J Hematol 1992; 41: 292-294.
89. Zanke BW, Rush DN, Jeffery JR, Israels LG. HTLV-1 T cell lymphoma in a cyclosporine-treated renal transplant patient. Transplantation 1989; 48: 695-697.
90. Goyal SB. Intestinal strongyloidiasis manifesting as eosinophilic pleural effusion. South Med J 1998; 91: 768-769.
91. Molbak K, Wested N, Hojlyng N, Scheutz F, Gottschau A, Aaby P, da Silva AP. The etiology of early childhood diarrhea: a community study from Guinea-Bissau. J Infect Dis 1994; 169: 581-587.
92. Gelber M, Rodrig J. Strongyloides stercoralis hyperinfection. Harefuah 1996; 130: 90-92.
93. de Thě G. Epstein-Barr virus and associated diseases. Course of Medical Virology, Institut Pasteur, 1995/1996. Ann Med Interne 1997; 148: 357-366.
94. Facer CA, Playfair JH. Malaria, Epstein-Barr virus, and the genesis of lymphomas. Adv Cancer Res 1989; 53: 33-72.
95. Patey O, Gessain A, Breuil J, Courillon-Mallet A, Daniel MT, Miclea JM, Roucayrol AM, Sigaux F, Lafaix C. Seven years of recurrent severe strongyloidiasis in an HTLV-1-infected man who developed adult T-cell leukaemia. Aids 1992; 6: 575-579.
96. Agape P, Copin MC, Cavrois M, Panelatti G, Plumelle Y, Ossondo-Landeau M, Quist D, Grossat N, Gosselin B, Fenaux P, Wattel E. Implication of HTLV-1 infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies). J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 394-402.
97. DeMars R, Held KR. The spontaneous azaguanine-resistant mutants of diploid human fibroblasts. Humangenetik 1972; 16: 87-110.
98. Hanabuchi S, Ohashi T, Koya Y, Kato H, Hasegawa A, Takemura F, Masuda T, Kannagi M. Regression of human T-cell leukemia virus type I (HTLV-1)-associated lymphomas in a rat model: peptide-induced T-cell immunity. J Natl Cancer Inst 2001; 93: 1775-1783.
99. Nowak MA, Bangham CR. Population dynamics of immune responses to persistent viruses. Science 1996; 272: 74-79.
100. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3: 205-211.
101. Chetouani F, Monestie P, Thebault P, Gaspin C, Michot B. ESSA: an integrated and interactive computer tool for analysing RNA secondary structure. Nucleic Acids Res 1997; 25: 3514-3522.
102. Gaspin C, Westhof E. An interactive framework for RNA secondary structure prediction with a dynamical treatment of constraints. J Mol Biol 1995; 254: 163-174.